2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

5838 Clinical predictors of measurable residual disease conversion kinetics in response to autologous stem cell transplantation in multiple myeloma

Hana Qasim, Fellow, Ryan F. Gebert2, Denise Kalos3, Hien Liu, MD4, Doris K. Hansen, MD5, Ciara Louise L Freeman, MD, PhD6, Taiga Nishihori, MD7, Omar Alexis Castaneda Puglianini, MD8, Lindsay Gardner9, Ariel Grajales-Cruz, MD10, Melissa Alsina, MD11, Brandon Blue, MD12, Daniel Deavila, MS13, Karun Neupane, MD14, Ariosto Siqueira Silva, PhD15, Kenneth H. Shain, MD, PhD16, Rachid Baz, MD17
1 H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
2 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
5 H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
6 H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
7 H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
8 H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
9 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
10 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
11 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
12 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
13 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
15 H Lee Moffitt Cancer Center, Tampa, United States
16 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
17 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Background

Autologous stem cell transplantation (ASCT) remains a cornerstone of therapy for eligible patients with multiple myeloma (MM), yet predictors of achieving deep measurable residual disease (MRD) responses following ASCT remain incompletely defined. Although MRD negativity is an established prognostic marker, the predictors and impact of MRD reduction by ASCT are not well characterized. We evaluated clinical, biologic, and treatment-related factors associated with quantitative MRD reduction and MRD conversion following first ASCT.

Methods

We performed a single-center retrospective study of adults with MM undergoing first ASCT between October 2017 and February 2026 who had paired pre- and post-ASCT MRD assessments by clonoSEQ. Quantitative MRD reduction was defined as the change in log₁₀ MRD burden between pre- and post-ASCT assessments. A prespecified offset was applied to include post-ASCT MRD-negative results in the analysis. MRD conversion from positive to negative was evaluated separately at the 10⁻⁵ and 10⁻⁶ thresholds. Patients positive before ASCT at either the 10⁻⁵ or 10⁻⁶ threshold were included in the overall cohort (n=317). Analyses of 10⁻⁵ conversion were restricted to patients positive at the 10⁻⁵ threshold before ASCT (n=258), whereas analyses of 10⁻⁶ conversion included the entire cohort. The following variables were evaluated: baseline MRD burden, age, sex, myeloma subtype, International Staging System (ISS) stage, high-risk FISH, induction regimen, quadruplet induction, number of induction cycles, and pre-ASCT response (≥VGPR). Predictors of quantitative MRD reduction were evaluated using multivariable linear regression with HC3 robust standard errors, whereas predictors of MRD conversion were evaluated using multivariable logistic regression. CD38-containing induction was evaluated in a sensitivity analysis because of collinearity with quadruplet induction.

Results

A total of 317 patients were included. Median age at diagnosis was 62.0 years (IQR, 56.0–66.9), 172 (56.2%) were male, and 40 of 257 evaluable patients (15.6%) had high-risk FISH abnormalities, defined as del(17p), gain/amplification of 1q, t(4;14), or t(14;16). MM subtypes included IgG (42.2%), light-chain-only disease (40.5%), IgA (12.4%), and other subtypes (4.9%). The median quantitative MRD reduction following ASCT was 0.81 log₁₀ (IQR, 0.25–1.37). Overall, 268 patients (85%) demonstrated a reduction in MRD burden, including 121 (38%) achieving a ≥1-log₁₀ reduction and 40 (13%) achieving a ≥2-log₁₀ reduction. MRD conversion occurred in 93 of 258 patients (36.0%) at the 10⁻⁵ threshold and 43 of 317 patients (13.6%) at the 10⁻⁶ threshold.

In the adjusted quantitative model, quadruplet induction was independently associated with greater quantitative MRD reduction (adjusted β 0.29; P=0.003), whereas male sex was associated with less MRD reduction (adjusted β −0.20; P=0.038). Increasing age was associated with greater MRD reduction (adjusted β 0.01 per year; P=0.034). Despite evaluation of multiple demographic, disease, and treatment-related characteristics, high-risk FISH, ISS stage, number of induction cycles, pre-ASCT response, myeloma subtype, and routine laboratory parameters were not independently associated with quantitative MRD reduction. Sensitivity analyses yielded similar results.

For MRD conversion, lower pre-transplant MRD burden independently predicted conversion at both the 10⁻⁵ (adjusted OR 0.16 per 1-log₁₀ increase; 95% CI, 0.08–0.30; P<0.001) and 10⁻⁶ (adjusted OR 0.37; 95% CI, 0.24–0.57; P<0.001) thresholds. Quadruplet induction was independently associated with higher odds of MRD conversion at both the 10⁻⁵ (adjusted OR 3.23; 95% CI, 1.68–6.21; P<0.001) and 10⁻⁶ (adjusted OR 6.38; 95% CI, 2.67–15.21; P<0.001) thresholds.

Conclusion

ASCT produced quantitative reductions in MRD burden in most patients with MM (85%), although the magnitude of response varied considerably. Baseline MRD burden and quadruplet induction were the principal determinants of achieving deep molecular response following ASCT. In contrast, conventional clinical and disease-related characteristics demonstrated limited association with short-term MRD kinetics. These findings suggest that predictors of early molecular response may differ from those driving long-term clinical outcomes and support prospective validation of MRD reduction as a clinically meaningful endpoint for response assessment following ASCT.

Hana Qasim, Fellow: No relevant conflicts of interest to declare.